CS
VINC

Credit Suisse’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Credit Suisse’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Hold
0
– – – 4364
2022
Q2 		– Hold
0
– – – 4406
2021
Q2 		– Sell
-1,328
Closed -$513K – 4645
2021
Q1 		$513K Buy
+1,328
New +$536K ﹤0.01% 3750

Other funds holding VINC

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Credit Suisse's VINC Position: Q3 2022 in Review

Credit Suisse held its Vincerx Pharma, Inc. Common Stock (VINC) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4364.

Credit Suisse first reported a position in VINC in Q1 2021 and has held it in 1 quarter since. The position peaked at $513K in Q1 2021. 42 funds tracked by Wall St. Rank hold VINC as of Q3 2022.

  • Credit Suisse held 0 shares of Vincerx Pharma, Inc. Common Stock worth $0 as of Q3 2022.
  • Credit Suisse left its Vincerx Pharma, Inc. Common Stock share count unchanged in Q3 2022.
  • Vincerx Pharma, Inc. Common Stock made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4364 holding.
  • Credit Suisse first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and has held it in 1 quarter since.
  • Credit Suisse's Vincerx Pharma, Inc. Common Stock position peaked at $513K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.